Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
Turnsek, Nina, Devjak, Rok, Edelbaher, Natalija, Osrajnik, Ilonka, Unk, Mojca, Vidovic, Dusanka, Jeric, Tina, Janzic, Urska
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy
Vrankar, Martina, Unk, Mojca
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
Ljubicic, Lidija, Janzic, Urska, Unk, Mojca, Terglav, Ana Sophie, Mohorcic, Katja, Seiwerth, Fran, Bitar, Lela, Badovinac, Sonja, Plestina, Sanja, Korsic, Marta, Kukulj, Suzana, Samarzija, Miroslav, Jakopovic, Marko
![[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647355c34e662f30ba53aa2a/cover-image.jpg)
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
Valentinuzzi, Damijan, Vrankar, Martina, Boc, Nina, Ahac, Valentina, Zupancic, Ziga, Unk, Mojca, Skalic, Katja, Zagar, Ivana, Studen, Andrej, Simoncic, Urban, Eickhoff, Jens, Jeraj, Robert